Biosensors International Group, Ltd. ("Biosensors" or the "Company", Bloomberg: BIG SP; Reuters: BIOS.SI; SGX: B20), a developer, manufacturer and marketer of innovative medical devices, has announced CE Mark approval for BioMatrix NeoFlex™, the latest addition to the BioMatrix family of drug-eluting stents (DES). BioMatrix NeoFlex features a new advanced stent delivery system, improving pushability, trackability and crossability. It also has a lower lesion entry profile than its predecessor.
BioMatrix NeoFlex retains the same unique combination of abluminal biodegradable polymer coating, proprietary limus drug Biolimus A9™ (BA9™) and flexible platform which has made the BioMatrix stent family an ...